A Double-Blind, Randomised, Placebo-Controlled, Multicentre Study Evaluating the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Latest Information Update: 18 Jul 2025
At a glance
- Drugs Baxdrostat (Primary)
- Indications Hypertension; Resistant hypertension
- Focus Registrational; Therapeutic Use
- Acronyms BaxAsia
- Sponsors AstraZeneca
Most Recent Events
- 08 Jul 2025 Planned End Date changed from 20 May 2026 to 3 Apr 2026.
- 08 Jul 2025 Planned primary completion date changed from 20 May 2026 to 24 Nov 2025.
- 08 Jul 2025 Status changed from recruiting to active, no longer recruiting.